Corvus Pharmaceuticals, Inc. (CRVS)
- Previous Close
1.5100 - Open
1.4700 - Bid 1.4300 x 100
- Ask 1.5100 x 100
- Day's Range
1.4101 - 1.5200 - 52 Week Range
1.0000 - 4.1900 - Volume
64,873 - Avg. Volume
198,785 - Market Cap (intraday)
72.577M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5600 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.63
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
www.corvuspharma.comRecent News: CRVS
Performance Overview: CRVS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRVS
Valuation Measures
Market Cap
72.58M
Enterprise Value
46.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.88
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.63%
Return on Equity (ttm)
-57.02%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-27.03M
Diluted EPS (ttm)
-0.5600
Balance Sheet and Cash Flow
Total Cash (mrq)
27.15M
Total Debt/Equity (mrq)
3.55%
Levered Free Cash Flow (ttm)
-15.79M